Enochian Biosciences, Inc. (ENOB) financial statements (2022 and earlier)

Company profile

Business Address CENTURY CITY MEDICAL PLAZA
SUITE 906 LOS ANGELES, CA 90067
State of Incorp. DE
Fiscal Year End June 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:13,42420,2878,16012,28215,3513,442
Cash and cash equivalents13,70820,6648,69612,28215,6013,942
Other undisclosed cash, cash equivalents, and short-term investments(284)(377)(536) (250)(500)
Receivables 2221123224
Prepaid expense9112332431923833
Other undisclosed current assets284377536 250500
Total current assets:14,61920,8998,94112,49515,7624,199
Noncurrent Assets
Operating lease, right-of-use asset  1,704
Property, plant and equipment669719    
Intangible assets, net (including goodwill)  166,541166,557163,735124
Goodwill  11,64011,64011,640 
Intangible assets, net (excluding goodwill)  154,901154,917152,095124
Deposits noncurrent assets  1381381383
Other noncurrent assets167,849167,987    
Other undisclosed noncurrent assets     196
Total noncurrent assets:168,518168,706168,383166,695163,873323
Other undisclosed assets  77868827 
TOTAL ASSETS:183,136189,605178,102179,877179,6624,522
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities671 1,064875639665
Accounts payable167 593539572435
Accrued liabilities504 47133767230
Debt4,728     
Due to related parties   2352351,923
Other liabilities500     
Other undisclosed current liabilities3031,886271  402
Total current liabilities:6,2021,8861,3351,1108742,989
Noncurrent Liabilities
Long-term debt and lease obligation2,2855,8186,113   
Long-term debt, excluding current maturities1,2004,5794,581   
Operating lease, liability1,0851,2391,532
Liabilities, other than long-term debt9,0306,0383,182   
Business combination, contingent consideration, liability9,0306,0383,182   
Other undisclosed noncurrent liabilities 3,0861,2005,66722,891 
Total noncurrent liabilities:11,31514,94210,4955,66722,891 
Total liabilities:17,51716,82811,8306,77723,7652,989
Stockholders' equity
Stockholders' equity attributable to parent, including:165,619174,663166,272173,100155,8981,533
Common stock555541
Additional paid in capital273,540265,580230,497225,765193,28429,622
Accumulated other comprehensive income (loss)(19)(11)(41)102206353
Accumulated deficit(107,907)(90,912)(64,188)(52,772)(37,595)(28,444)
Other undisclosed stockholders' equity attributable to parent    (0) 
Total stockholders' equity:165,619174,663166,272173,100155,8981,533
Other undisclosed liabilities and equity (1,886)    
TOTAL LIABILITIES AND EQUITY:183,136189,605178,102179,877179,6624,522

Income statement (P&L) ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
Gross profit:(3,856)     
Operating expenses(31,109)(23,402)(11,924)(10,990)(8,169)(2,400)
Other undisclosed operating income3,891     
Operating loss:(31,073)(23,402)(11,924)(10,990)(8,169)(2,400)
Nonoperating income (expense)(7,317)(3,447)507(7,026)(1,094)193
Foreign currency transaction gain (loss), before tax(10)(33)147(26)290219
Interest and debt expense(183)(380)140(0)(143)(11)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes183380(140)014311
Loss from continuing operations before income taxes:(38,390)(26,849)(11,416)(18,016)(9,264)(2,208)
Income tax benefit1125  11265
Net loss available to common stockholders, diluted:(38,389)(26,724)(11,416)(18,016)(9,152)(2,143)

Comprehensive Income ($ in thousands)

12/31/2021
TTM
6/30/2021
6/30/2020
6/30/2019
6/30/2018
6/30/2017
Net loss:(38,389)(26,724)(11,416)(18,016)(9,152)(2,143)
Other comprehensive income (loss)(16)31(143)(104)(147)(211)
Comprehensive loss:(38,404)(26,693)(11,560)(18,120)(9,299)(2,354)
Other undisclosed comprehensive loss, net of tax, attributable to parent  (40)   
Comprehensive loss, net of tax, attributable to parent:(38,404)(26,693)(11,600)(18,120)(9,299)(2,354)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: